Prof Kenneth Anderson (Harvard Medical School, Boston, MA) chairs a discussion with Prof Leif Bergsagel (Mayo Clinic, Scottsdale, AZ) and Prof Gareth Morgan (University of Arkansas, Fayetteville, AR) on studies of potential new avenues for the treatment of multiple myeloma (MM). They focus on the clinical significance of tumour heterogeneity in MM, the utilisation of genomics for improved classification of MM subtypes and the development of rationally based combination therapies for MM.
Clinical significance of progenitor cells in multiple myeloma
12 May 2015
Hematology
